Medical devices, healthcare technology and the business of care
PMA approval · P220015

DilightTM (roflufocon E) Overnight Orthokeratology Contact Lens

Tianjin MasterVision Technology Co., Ltd. · Decision date Aug 5, 2026

FDA DECISIONP220015

What did the FDA approve?

FDA records P220015 as an original PMA application. The recorded decision is approval, dated Aug 5, 2026.

FDA approval order statement

Approval for DilightTM (roflufocon E) Overnight Orthokeratology Contact Lens. The lenses are indicated for use in the reduction of myopic refractive error in non-diseased eyes. The lens is indicated for overnight wear for the temporary reduction of myopia up to 4.00 diopters (manifest spherical equivalent) in eyes with astigmatism up to 1.50 diopters. The lenses may only be disinfected using a chemical disinfection system. Note: To maintain the Orthokeratology effect overnight lens wear must be continued on a prescribed schedule. Failure to do so can affect daily activities (e.g., night driving), cause visual fluctuations, and changes in intended correction.
Regulatory pathway
Original PMA
Clinical specialty
Ophthalmic
Decision date
Aug 5, 2026

FDA source record

Regulatory record facts

Identifier
P220015
Regulatory pathway
Premarket approval application
Product code
NUU
Decision code
APPR
Decision date
Aug 5, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lens, contact, orthokeratology, overnight.

Product code
NUU
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P220015 received

    Application receipt date recorded by FDA.

  2. P220015 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P220015. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code NUU

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Tianjin MasterVision Technology Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
# 89 Heyuan Rd., Jing-Jin Technology Valley, 1st Floor # 15 Bldg., Tianjin, 301721

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records